New high-resolution prototype versus standard spectralis optical coherence tomography in patients with central serous chorioretinopathy.
Acute CSC
Biomarkers
CSC
Central serous chorioretinopathy
Chronic CSC
High-res OCT
Standard OCT
Journal
International journal of retina and vitreous
ISSN: 2056-9920
Titre abrégé: Int J Retina Vitreous
Pays: England
ID NLM: 101677897
Informations de publication
Date de publication:
16 Oct 2024
16 Oct 2024
Historique:
received:
23
08
2024
accepted:
06
10
2024
medline:
17
10
2024
pubmed:
17
10
2024
entrez:
16
10
2024
Statut:
epublish
Résumé
To assess the accuracy of High-Resolution OCT in detecting biomarkers associated with central serous chorioretinopathy (CSC) compared to standard OCT. We conducted a cross-sectional study involving CSC patients who underwent High-Resolution and standard OCT during the same visit. Using the SPECTRALIS High-Res OCT device (Heidelberg Engineering, Heidelberg, Germany), macular B-scans were obtained and compared with those acquired using a SPECTRALIS HRA + OCT device (Heidelberg Engineering, Heidelberg, Germany). Qualitative assessments were performed, and statistical analyses compared the performance of both OCT modalities. Thirty-one patients diagnosed with CSC were included with a mean age of 56.3 years (± 10.2). Among them, 29% (n = 9) were classified as acute CSC (aCSC), while 71% (n = 22) had chronic CSC (cCSC). High-Resolution OCT outperformed standard OCT in detecting microstructural changes in the outer retinal layers, including a higher prevalence of disrupted interdigitation zone (IZ) (29% vs. 6%, p = 0.003) and retinal pigment epithelium (RPE) disruption (12% vs. 2%, p = 0.0024). Intergrader agreement was high (Cohen's Kappa = 0.85). High-Resolution OCT demonstrates promise in identifying critical biomarkers associated with CSC, particularly disruptions in the IZ and RPE. Further validation in larger cohorts is required to confirm their clinical relevance in patients with CSC.
Identifiants
pubmed: 39415240
doi: 10.1186/s40942-024-00598-6
pii: 10.1186/s40942-024-00598-6
doi:
Types de publication
Journal Article
Langues
eng
Pagination
78Informations de copyright
© 2024. The Author(s).
Références
Feenstra HMA, van Dijk EHC, Cheung CMG et al. Central serous chorioretinopathy: an evidence-based treatment guideline. Prog Retin Eye Res 2024:101236.
Fung AT, Yang Y, Kam AW. Central serous chorioretinopathy: a review. Clin Exp Ophthalmol. 2023;51(3):243–70.
doi: 10.1111/ceo.14201
pubmed: 36597282
Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82–118.
doi: 10.1016/j.preteyeres.2015.05.003
pubmed: 26026923
Nkrumah G, Paez-Escamilla M, Singh SR, et al. Biomarkers for central serous chorioretinopathy. Ther Adv Ophthalmol. 2020;12:2515841420950846.
doi: 10.1177/2515841420950846
pubmed: 32923941
pmcid: 7448152
Desideri LF, Scandella D, Berger L, Sznitman R, Zinkernagel M, Anguita R. Prediction of chronic central serous chorioretinopathy through combined manual annotation and AI-assisted volume measurement of flat irregular pigment epithelium. Ophthalmologica 2024.
Yoneyama S, Fukui A, Sakurada Y, et al. Distinct characteristics of simple Versus Complex Central Serous Chorioretinopathy. Retina. 2023;43(3):389–95.
doi: 10.1097/IAE.0000000000003692
pubmed: 36729824
Rothenbuehler SP, Malmqvist L, Belmouhand M et al. Comparison of spectral-domain OCT versus swept-source OCT for the detection of Deep Optic Disc Drusen. Diagnostics (Basel). 2022;12(10).
Reche J, Stocker AB, Henchoz V, et al. High-resolution optical coherence tomography in healthy individuals provides Resolution at the Cellular and subcellular levels. Transl Vis Sci Technol. 2023;12(7):12.
doi: 10.1167/tvst.12.7.12
pubmed: 37428129
pmcid: 10341292
Ferro Desideri L, Barra F, Ferrero S. Methodological concerns on retinal and choroidal thickness variations measured by optical coherence tomography in patients with epilepsy. Epilepsy Behav. 2019;94:312.
doi: 10.1016/j.yebeh.2019.02.027
pubmed: 30982684
Singh SR, Iovino C, Zur D, et al. Central serous chorioretinopathy imaging biomarkers. Br J Ophthalmol. 2022;106(4):553–8.
doi: 10.1136/bjophthalmol-2020-317422
pubmed: 33288526
Habra O. High resolution optical coherence tomography in patients with age related macular degeneration. IOVS ARVO Abstract.; 2022. https://iovs.arvojournals.org/article.aspx?articleid=2782799 .
Matsumoto H, Sato T, Kishi S. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. Am J Ophthalmol. 2009;148(1):105–10. e101.
doi: 10.1016/j.ajo.2009.01.018
pubmed: 19327740
Ratanasukon M, Thongthong K, Bhurayanontachai P, Jirarattanasopa P. Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy. Clin Ophthalmol. 2013;7:87–92.
doi: 10.2147/OPTH.S39584
pubmed: 23345962
pmcid: 3548438
Asano KS, Asaoka R, Asano S, Azuma K, Inoue T, Obata R. Elongated photoreceptor outer segment length and prognosis of Chronic Central Serous Chorioretinopathy. Retina. 2020;40(4):750–7.
doi: 10.1097/IAE.0000000000002445
pubmed: 30640283
Fujita K, Imamura Y, Shinoda K, et al. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2015;122(3):555–61.
doi: 10.1016/j.ophtha.2014.09.034
pubmed: 25444637
Nicholson BP, Ali Idris AM, Bakri SJ. Central Serous Chorioretinopathy: clinical characteristics Associated with visual outcomes. Semin Ophthalmol. 2018;33(6):804–7.
doi: 10.1080/08820538.2018.1503690
pubmed: 30067427
Torres-Costa S, Penas S, Cerqueira AR, et al. Long term outer retinal changes in central serous chorioretinopathy submitted to half-dose photodynamic therapy. Photodiagnosis Photodyn Ther. 2021;34:102235.
doi: 10.1016/j.pdpdt.2021.102235
pubmed: 33631379
Piccolino FC, de la Longrais RR, Ravera G, et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol. 2005;139(1):87–99.
doi: 10.1016/j.ajo.2004.08.037
pubmed: 15652832
Paques M, Tadayoni R, Sercombe R, et al. Structural and hemodynamic analysis of the mouse retinal microcirculation. Invest Ophthalmol Vis Sci. 2003;44(11):4960–7.
doi: 10.1167/iovs.02-0738
pubmed: 14578423
Wong RL, Singh SR, Rasheed MA, et al. En-face choroidal vascularity in central serous chorioretinopathy. Eur J Ophthalmol. 2021;31(2):536–42.
doi: 10.1177/1120672120908719
pubmed: 32103680
Anderson DH, Guerin CJ, Erickson PA, Stern WH, Fisher SK. Morphological recovery in the reattached retina. Invest Ophthalmol Vis Sci. 1986;27(2):168–83.
pubmed: 3943943
Rex TS, Fariss RN, Lewis GP, Linberg KA, Sokal I, Fisher SK. A survey of molecular expression by photoreceptors after experimental retinal detachment. Invest Ophthalmol Vis Sci. 2002;43(4):1234–47.
pubmed: 11923271
Gupta V, Gupta P, Dogra MR, Gupta A. Spontaneous closure of retinal pigment epithelium microrip in the natural course of central serous chorioretinopathy. Eye (Lond). 2010;24(4):595–9.
doi: 10.1038/eye.2009.193
pubmed: 19648895
Hirami Y, Tsujikawa A, Sasahara M, et al. Alterations of retinal pigment epithelium in central serous chorioretinopathy. Clin Exp Ophthalmol. 2007;35(3):225–30.
doi: 10.1111/j.1442-9071.2006.01447.x
pubmed: 17430508
Subhi Y, Forshaw T, Sorensen TL. Macular thickness and volume in the elderly: a systematic review. Ageing Res Rev. 2016;29:42–9.
doi: 10.1016/j.arr.2016.05.013
pubmed: 27262495
Kalra G, Cetin H, Whitney J et al. Automated identification and segmentation of Ellipsoid Zone At-Risk using deep learning on SD-OCT for Predicting Progression in Dry AMD. Diagnostics (Basel). 2023;13(6).
Berlin A, Matney E, Jones SG, et al. Discernibility of the Interdigitation Zone (IZ), a potential optical coherence tomography (OCT) biomarker for visual dysfunction in aging. Curr Eye Res. 2023;48(11):1050–6.
doi: 10.1080/02713683.2023.2240547
pubmed: 37539829